Revelation Biosciences Inc Ordinary Shares REVB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
-
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
-
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
-
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
Trading Information
- Previous Close Price
- $3.72
- Day Range
- $3.56–3.68
- 52-Week Range
- $3.08–40.60
- Bid/Ask
- $3.56 / $3.79
- Shares Outstanding
- 569,059.00
- Market Cap
- $2.09M
- Volume/Avg
- 3,440 / 10,385
Key Statistics
- Price/Earnings (Normalized)
- 0.10
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.revbiosciences.com
Valuation
|
Metric
|
REVB
|
|---|---|
Price/Earnings (Normalized) | 0.10 |
Price/Book Value | 0.21 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
REVB
Financial Strength
|
Metric
|
REVB
|
|---|---|
Quick Ratio | 6.11 |
Current Ratio | 6.21 |
Interest Coverage | — |
Quick Ratio
REVB
Profitability
|
Metric
|
REVB
|
|---|---|
Return on Assets (Normalized) | −82.85% |
Return on Equity (Normalized) | −101.70% |
Return on Invested Capital (Normalized) | −97.04% |
Return on Assets
REVB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#r>LyD | LOCK|fX<f | $134B | |||
| Moderna Inc
MRNA
| LOCK|lw$!$> | LOCK|?N | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@N&J@@ | LOCK|ww?>% | $84B | |||
| argenx SE ADR
ARGX
| LOCK|w@<&&&j | LOCK|yTW | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Kgy%w<# | LOCK|Lq | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$v&Qq^ | LOCK|p#fCK | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Hr!&VF? | LOCK|dYBY | $29B | |||
| Incyte Corp
INCY
| LOCK|#&!@@h# | LOCK|RD | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|#dD@r?G | LOCK|%S% | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|CPZ$vc | LOCK|&> | $14B |
United States